NASDAQ:IMVT 20 May 2026

Roivant stock set for new test after big move on drug data
·····

Roivant stock set for new test after big move on drug data

Roivant Sciences shares rose 1.2% to $30.31 in light premarket trading Tuesday after last week’s 14% surge on positive IMVT-1402 drug data. Immunovant, developing the autoimmune drug, jumped 31% last week despite reporting a larger loss than expected. BofA raised its price target to $31.50 but kept a Neutral rating, while Citi and TD Cowen lifted targets and maintained Buy calls. U.S. markets reopened after the Memorial Day holiday.
May 26, 2026
ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data
······

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data

argenx SE shares rose 0.7% to $803.67 Wednesday, trailing biotech peers after Immunovant reported positive rheumatoid arthritis trial data for IMVT-1402, sending its stock up 35.1%. VYVGART sales reached $1.3 billion last quarter. The FDA recently expanded VYVGART’s approval for generalized myasthenia gravis. argenx’s next key data releases are expected later this year.
May 20, 2026

Stock Market Today

  • DroneShield: A Strategic ASX Growth Share Amid Rising Counter-Drone Demand
    May 29, 2026, 7:32 PM EDT. DroneShield Ltd (ASX: DRO) targets the growing security threat posed by drones. Its niche focus on anti-drone technology positions it in a market driven by increasing defence and government demand. The company combines hardware and artificial intelligence-enabled software to counter evolving drone tactics, aiming to build recurring software revenue alongside hardware sales. Recent financial updates reveal strong cash flow, a robust sales pipeline, and global operational presence. While the potential is significant, defence contracts remain unpredictable, requiring cautious investor evaluation. DroneShield's blend of technology and strategic resources suggests it could be a compelling ASX growth share for long-term investors watching the defense tech sector.